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Huntington’s disease (HD) is a fatal degenerative auto-
somal dominant neuropsychiatric disease that causes 
neuronal death and is characterized by progressive stri-
atal and then widespread brain atrophy. Brain-derived 
neurotrophic factor (BDNF) is a lead candidate for the 
treatment of HD, as it has been shown to prevent cell 
death and to stimulate the growth and migration of 
new neurons in the brain in transgenic mouse models. 
BDNF levels are reduced in HD postmortem human 
brain. Previous studies have shown efﬁcacy of mesen-
chymal stem/stromal cells (MSC)/BDNF using murine 
MSCs, and the present study used human MSCs to 
advance the therapeutic potential of the MSC/BDNF 
platform for clinical application. Double-blinded stud-
ies were performed to examine the effects of intra-
striatally transplanted human MSC/BDNF on disease 
progression in two strains of immune-suppressed HD 
transgenic mice: YAC128 and R6/2. MSC/BDNF treat-
ment decreased striatal atrophy in YAC128 mice. MSC/
BDNF treatment also signiﬁcantly reduced anxiety 
as measured in the open-ﬁeld assay. Both MSC and 
MSC/BDNF treatments induced a signiﬁcant increase 
in neurogenesis-like activity in R6/2 mice. MSC/BDNF 
treatment also increased the mean lifespan of the R6/2 
mice. Our genetically modiﬁed MSC/BDNF cells set a 
precedent for stem cell-based neurotherapeutics and 
could potentially be modiﬁed for other neurodegen-
erative disorders such as amyotrophic lateral sclerosis, 
Alzheimer’s disease, and some forms of Parkinson’s 
disease. These cells provide a platform delivery system 
for future studies involving corrective gene-editing 
 strategies.
Received 9 August 2015; accepted 5 December 2015; advance online  
publication 15 March 2016. doi:10.1038/mt.2016.12
INTRODUCTION
Huntington’s disease (HD) is a fatal, degenerative autosomal dom-
inant neuropsychiatric disease that afflicts nearly one in 10,000 
people in the United States. HD is caused by an expanded CAG 
trinucleotide repeat region located in exon 1 of the huntingtin 
gene. The HD mutation causes neuronal death and is character-
ized initially by striatal atrophy with later generalized brain atro-
phy.1 Clinical symptoms include progressive cognitive decline, 
psychiatric symptoms, and chorea. Currently available medica-
tions are strictly palliative and target only some symptoms of the 
disease, such as chorea and psychiatric features.2–4 There are no 
available treatments to attenuate the underlying neuronal cell 
death and subsequent striatal atrophy seen in HD.
Previous studies have shown brain-derived neurotrophic fac-
tor (BDNF) to be a putative candidate for the treatment of HD. 
BDNF is known to mediate both the survival and function of stri-
atal neurons.5 Both cortical and striatal BDNF levels are reduced 
in postmortem HD brain6,7 due to inhibition of BDNF expres-
sion levels at the transcriptional level by the mutant huntingtin 
protein. This reduction in BDNF in the striatum correlates with 
symptom onset and heightened severity of the disease in trans-
genic HD mice.5 BDNF knockout mice recapitulate the striatal 
atrophy phenotype of HD patients and indicate that reduced neu-
rotrophic support in the striatum is a major factor contributing to 
neurodegeneration in HD.8 BDNF expression levels are lowered 
in transgenic mouse models of HD and the restoration of BDNF 
expression levels has been shown to have prosurvival effects on 
neurons and ameliorate HD symptoms.5,9–35 Therefore, BDNF is 
considered a prime candidate to treat the underlying neuronal 
loss seen in HD (reviewed in refs. 36,37).
Effective delivery of BDNF for neurological disorders remains 
a major challenge due to its very short half-life, which severely 
limits the effectiveness of the recombinant protein. Several stud-
ies have examined various exogenous delivery methods that may 
be utilized to translate BDNF based therapeutics to the clinic. 
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Benraiss et al.20 used adeno-associated virus (AAV) vectors to 
express BDNF in striatal neurons and demonstrated that AAV 
delivery of BDNF-induced neurogenesis and promoted a longer 
lifespan in a murine model of HD. Interestingly, this benefit was 
potentiated by a factor secreted by mesenchymal stem/stromal 
cells (MSCs), noggin.38–41 However, efforts to translate AAV vector 
therapeutics in the clinic have been hampered by their immuno-
genic properties.
The Dunbar laboratory has shown murine MSCs engineered 
to overexpress BDNF had significant ameliorative effects on dis-
ease progression in a transgenic mouse model of HD.27 These 
studies demonstrated that murine MSC/BDNF implanted into the 
striata significantly increased improved motor performance and 
reduced HD associated movement disorders.27 The present study 
used human MSCs to advance the therapeutic potential of the 
MSC/BDNF platform for potential clinical application.
MSCs were chosen as the delivery platform for BDNF since 
they are known to secrete a variety of neurotrophic and other fac-
tors that reduce inflammation, reduce programmed cell death, 
enhance connections between neurons, and reduce cell toxicity.42 
MSCs have been shown to be readily engineered using viral vec-
tors to robustly deliver growth factors.43,44 Using gene-modified 
MSCs as a delivery strategy addresses certain safety concerns 
involved with the direct use of viral vectors, as MSCs do not 
permanently engraft into host tissues. In addition, MSCs do not 
require immunosuppression following allogeneic transplantation, 
and have a strong, demonstrable safety profile in clinical trials.45–53
MSC/BDNF combines the beneficial effects of BNDF admin-
istration to the striata along with the benefits of MSC secreted fac-
tor supplementation (e.g., noggin). Unlike direct BDNF delivery 
via viral vector injection or recombinant protein administration 
into the brain, MSCs migrate into areas of tissue damage and have 
been shown to have numerous tissue healing effects (reviewed 
in ref. 42). Studies have shown MSCs do not permanently engraft 
into host tissues; however, the duration and strategic localization 
of BDNF production should be adequate to produce a beneficial 
effect in the HD striata by promoting neurogenesis. We hypoth-
esize that the neurorestorative effects of BDNF will outlast the 
survival of MSCs. This is supported by animal data from our labo-
ratory and others.20,27,54–60
The YAC128 mouse model was used in the behavioral and stria-
tal volume studies. This strain provides expression of a full length 
human huntingtin gene with 128 CAG repeats. The YAC128 strain 
is an excellent model for HD which recapitulates the slow decline 
in motor and behavioral function and the progressive striatal loss 
and neuropathology that are seen in human HD. Motor, striatal and 
behavioral deficits are not seen until 7–12 months in this strain. We 
used this strain with immune suppression to measure the attenua-
tion of striatal decline by a cell therapy candidate, MSC/BDNF. We 
also used it to measure a decrease in overall anxiety caused by our 
cell therapy product, as measured in the open-field assay.
The R6/2 strains have rapid onset and progression. We per-
formed neurogenesis assays in the R6/2 (CAG 120) mouse model 
of HD due to their early disease progression and very rapid decline, 
which is more like the rapidly progressing juvenile HD (JHD), 
than adult HD. The R6/2 strain only lives for 13–17 weeks in our 
colony, making repeated measures after immune suppression and 
surgery difficult. However, they are a useful HD strain for measur-
ing the effects of MSC/BDNF and other agents on neurogenesis.
In order for therapies to be effectively translated into the 
clinic, safety and efficacy must first be demonstrated in preclini-
cal animal studies. However, efficacy testing of human stem cell 
therapeutics in transgenic mouse models is challenging as human 
cells can be rejected from immune competent mice via a xeno-
geneic immune response. Currently, no immune-deficient mouse 
models of HD exist; therefore, we used an immunosuppressive 
regimen (FK506 and rapamycin) which permitted retention of 
human MSC/BDNF cells up to 28 days postimplantation, which 
was similar to the results observed in the severely immunodefi-
cient NOD/SCID/Gamma chain -/- (NSG) strain. Development 
of this immune suppression regimen permitted efficacy testing 
of the MSC/BDNF in two immunocompetent transgenic animal 
models of HD, YAC128, and R6/2.
Our data demonstrate that intrastriatal delivery of human 
MSC/BDNF significantly reduced anxiety-like behaviors and 
significantly increased neurogenesis in immune suppressed HD 
mouse models, with a trend toward increased survival. A signifi-
cant decrease in striatal volume was striatal volume was observed 
between vehicle-treated HD mice and wild type mice, but was not 
observed in the HD mice that received MSC/BDNF. This recov-
ery may be due to the stimulation and maturation of endogenous 
neurogenesis promoted by BDNF, and enhanced by the secretion 
of various complementary therapeutic factors by MSCs.
RESULTS
MSC/BDNF: vector integration and characterization
Human MSCs were obtained from the bone marrow of qualified 
allogeneic donors and were engineered to secrete elevated levels 
of BDNF via lentiviral transduction. The use of lentiviral trans-
duction ensures consistent, sustained expression of BDNF for the 
duration of the survival of these cells within the striata. In addi-
tion, clinical products must be consistent from batch to batch 
to ensure consistency of any therapeutic benefit, which can be 
ensured by lentiviral transduction using a standardized titer at a 
fixed, experimentally determined multiplicity of infection (MOI).
A schematic of the lentiviral vector used in the current stud-
ies, pCCLc-MNDU3-BDNF-WPRE is shown in Figure 1a. pCCLc 
was used as the backbone for this third generation lentiviral vec-
tor, as originally described by Dull et al.61 The MNDU3 promoter 
was generated in the laboratory of Dr. Donald Kohn and consists 
of the U3 region of the MND oncoretroviral vector.62 The MNDU3 
promoter is a strong promoter and particularly useful for constitu-
tive expression of proteins. It has already been used as a retroviral 
vector backbone in a stem cell gene therapy clinical trial for ade-
nosine deaminase (ADA) deficiency without adverse events, over a 
10-year follow-up period in hematopoietic stem cells.63 Woodchuck 
postregulatory element (WPRE), the woodchuck hepatitis virus 
post-transcriptional regulatory element, increases mRNA levels 
post-transcriptionally, but is not likely to activate any oncogene, as 
it is not a promoter.
This BDNF expression vector was used to transduce human bone 
marrow derived MSCs at increasing MOI. Subsequently, integration 
rates were assessed. To determine whether there were any deletions 
or rearrangements in vector-transduced cells, genomic polymerase 
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chain reaction (PCR) was performed. The stability of our  integrated 
BDNF lentiviral vector was evaluated by PCR with genomic 
DNA from transduced cells. The BDNF transgene was continu-
ously present after integration and structurally stable (Figure 1b). 
Bands were of the expected size, as shown in the schema.
BDNF production
MSC/BDNF cells were thawed and incubated in 20% O2 for 24 
hours, followed by incubation in 1% O2 for 48 hours. No differences 
in morphology or rate of senescence were detected between gene-
modified cells (MSC/BDNF) and unmodified MSCs (Figure 2a). 
Figure 1  Vector map and stability. (a) Vector map diagram for pCCLc-MNDU3-BDNF-WPRE. A third-generation lentiviral vector, based on the 
pCCLc-x backbone was used to generate a BDNF gene construct. The transgene is driven by the MNDU3 promoter, a constitutive RNA polymerase 
II promoter. BDNF is the gene encoding brain-derived neurotrophic factor, cloned in our lab from adult human bone marrow-derived MSCs. WPRE is 
the woodchuck hepatitis post-transcriptional regulatory element, which acts in cis to enhance gene expression. (b) Stability of the clinical vector in 
transduced cells. To determine whether there were any deletions or rearrangements in vector-transduced cells, genomic PCR was performed. MSCs 
were transduced with the BDNF vector at MOI 10 or MOI 20. Total genomic DNA was extracted and analyzed by PCR with primers speciﬁc for the 
respective vector segments. (I) ψ (forward) and U5-3’ (reverse), (II) ψ (forward) and MNDU3 (reverse), (III) MNDU3 (forward) and BDNF (reverse), 
and (IV) BDNF (forward) and U5-3’ (reverse). Resulting DNA was run on a gel in the following lanes: 1 kb DNA ladder (DLa), nontransduced MSCs 
(negative control, lane 1), BDNF MOI 10 MSCs (lane 2), BDNF MOI 20 MSCs (lane 3), BDNF vector plasmid (positive control, lane 4), no template 
control (lane 5). Bands were of the expected size, as shown in the schematic of the PCR products below the panels. Ψ, psi packaging sequence; BDNF, 
brain-derived neurotrophic factor; WPRE, woodchuck hepatitis virus post-transcriptional regulatory element.
Dla 1 2 3 4 5
pCCLc-MNDU3c-BDNF-WPRE
7987 bp
Dla 1 2 3 4 5
Dla
cppt
MNDU3 BDNF WPRE
U5-3′ψ
1 2 3 4 5
−3.8 kb
−0.8 kb
−1.6 kb
−1.4 kb
Dla 1 2 3 4 5
I
I
II
III
IV
II
III IV
a
b
Molecular Therapy vol. 24 no. 5 may 2016 967
Ofﬁcial journal of the American Society of Gene & Cell Therapy
Human MSC/BDNF as a Proposed Therapeutic for Huntington’s Disease
Media was changed to serum-free media after 24 hours in 1% O2 
and the resulting conditioned media was collected for ELISA after an 
additional 24 hours (Figure 2b). As expected, we observed increased 
BDNF production by MSC/BDNF as we increased the MOI. The 
MSC/BDNF MOI 10 cell bank generated for use in our efficacy stud-
ies produced 10.9 ng of BDNF per 2 × 105 cells in 24 hours (MOI 20 
produced 18.1 ng of BDNF per 2 × 105 cells in 24 hours).
Vector copy number and post-transduction MSC/
BDNF characterization
Human MSCs were transduced with pCCLc-MNDU3-BDNF-
WPRE, cryopreserved, thawed and expanded for 3 days. DNA was 
isolated and used for qPCR analysis. Quantification was based on 
standard curves of plasmid DNA. Vector copy number/cell was 
determined as WPRE/2GAPDH, since WPRE is found only in 
the vector and each cell has two copies of the GAPDH gene. The 
MOIs of 10 and 20 produced MSC/BDNF with optimal BDNF 
levels, as shown in Figure 2b, and resulted in 0.5–2 integrated 
copies of vector DNA per cell, which falls within recommenda-
tions provided by the Food and Drug Administration (Figure 2c).
To confirm that the differentiation potential of MSC/BDNF 
cells was not affected by transduction, we performed osteogenic 
and adipogenic differentiation assays of both transduced and non-
transduced MSCs. As shown in Figure 3a, we observed similar 
levels of osteogenesis and adipogenesis across both transduced 
and nontransduced MSCs. In addition, there were no observed 
differences in cell proliferation between these cell populations 
(Figure 3b). In summary, no alterations in phenotype, morphol-
ogy, proliferation rate, or differentiation capacity were observed 
Figure 2 Cell characterization. (a) Cells transduced by the BDNF vec-
tor (right), display the size and phenotypic appearance of healthy non-
transduced MSCs from the same donor (left). (b) In vitro characterization 
showed that human MSCs transduced with the pivotal BDNF lentiviral vec-
tor at multiplicities of infection (MOI) 2, 5, 10, and 20 displayed a positive 
correlation between BDNF production and MOI. Supernatant was collected 
for determination of secreted BDNF by ELISA after conditioning serum free 
media for 24 hours. (c) Vector copy number at increasing MOI. Human 
MSCs were transduced with pCCLc-MNDU3-BDNF-WPRE, cryopreserved, 
then subsequently thawed and expanded for 3 days. DNA was isolated 
and used for qPCR analysis. Quantiﬁcation was based on standard curves of 
plasmid DNA. Vector copy number/cell was determined as WPRE/2GAPDH.
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in MSCs transduced by the lentiviral vector carrying the BDNF 
transgene, as compared to nontransduced MSCs.
In vivo retention studies
We tested the safety and efficacy of the human MSC/BDNF cells 
in two murine models of HD: YAC128 and R6/2. Since xenografts 
induce a potent immune response, efficacy studies should gen-
erally be performed in an immune deficient model; however, an 
immune deficient mouse model of HD does not currently exist. 
To address this we used an immune suppressive drug regimen 
(FK506 and Rapamycin) with both immunocompetent murine 
models of HD. Retention of intracranially transplanted MSCs was 
assayed with and without immune suppression (FK506/Rapa by 
Alzet osmotic pump) and compared to retention in the immune-
deficient mouse strain, NSG.
The NSG mouse strain is a highly immune-deficient mouse 
model and an excellent tool for the testing of human cell-based 
therapies. The NSG mouse is deficient in mature T and B cells, 
natural killer cells, serum immunoglobulin, a hemolytic comple-
ment system, and has shown the ability to stably engraft many 
types of human cells. For these reasons, we used NSG mice as 
positive controls in our retention assays.
Human MSCs were transduced by a lentiviral vector carrying 
the luciferase gene (pCCLc-MNDU3-Luc-PGK-EGFP-WPRE), 
which allows cells to be visualized in the brains of living mice over 
time using IVIS imaging. Mice received unilateral (left) intrastria-
tal injections of 2.5 × 105 cells and were subsequently imaged on 
days 2, 4, 7, 14, 21, and 28 postimplantation. As shown in Figure 4, 
human MSCs survived only 1 week in the brains of nonimmune 
suppressed mice. This rapid clearance occurred in spite of the fact 
that MSCs can shelter themselves from the immune system, to 
some extent. The immune privilege capacities of MSCs did not 
extend across species in our study.
In the immune-suppressed mice, MSCs could be detected in 
some mice for up to 28 days postimplantation, which was similar 
to the results observed in the immune-deficient NSG mouse con-
trol strain.
MSC/BDNF efﬁcacy: behavioral
To evaluate the behavioral therapeutic effects of MSC/BDNF 
treatment in YAC128 HD mice, we performed the open-field 
assay. Among other behavioral outcomes measured, the open-
field assay measures anxiety-related behavior, which is a major 
debilitating problem in HD. All YAC128 mice in the study were 
immune suppressed using FK506/Rapamycin delivered by an 
Alzet osmotic pump, as described in Figure 4. Mice were then 
implanted with vehicle, MSC, or MSC/BDNF at 8 ½ months of 
age, as most behavioral deficits are not apparent in the YAC128 
strain until 7–12 months of age. Behavioral testing was conducted 
weekly following cell implantation for 6 weeks, or until 10 months 
of age. Mice were then euthanized and brains were collected for 
histological analysis.
No motor deficits were observed in YAC128 mice during 
open-field testing, as measured by the total distance traveled, 
Figure 4 In vivo imaging demonstrates that immune suppression (of FVB/NJ mice) was able to increase cell retention to levels similar to that 
observed in immune-deﬁcient NSG mice for at least 28 days. Human MSCs were transduced by a lentiviral vector carrying the luciferase gene 
(pCCLc-MNDU3-Luc-PGK-EGFP-WPRE), which allows cells to be visualized (bioluminescence) in the brains of living mice over time.
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total movement time, number of exploratory vertical episodes, or 
number of stereotypic behaviors, (Figure 5a and data not shown). 
These data show that none of the tested groups displayed motor 
deficits during the time tested. Repeated measures analysis of 
variance revealed no significant between-group differences for 
total distance traveled (F(3,51) = 0.438, P = 0.727), total move-
ment time (F(3,51) = 2.537, P = 0.067), number of exploratory 
vertical episodes (F(3,51) = 0.836, P = 0.480), or number of ste-
reotypic behaviors (F(3,50) = 1.596, P = 0.202). This suggests that 
all mice exhibited similar spontaneous exploration of the box and 
that any differences observed in other behaviors was not due to 
motor impairment.
Anxiety is a hallmark symptom of HD in humans.64–66 In 
murine models, anxious mice spend less time in the center quad-
rant of an open field as anxiety increases. WT mice avidly explore 
the center of the open field, whereas transgenic HD mice move 
along the edges of box and only rarely leave this zone. This behav-
ior is analogous to fear or anxiety in humans. Sham-treated HD 
mice spent much less time in the center quadrant of the open field 
as compared to wild type controls, indicating the HD mice were 
displaying higher levels of anxiety as expected. This display of anx-
iety is attenuated in HD mice that were treated with MSC/BDNF 
(Figure 5b). Repeated measures analysis of variance revealed a 
significant between-group difference (F(3,50) = 4.305, P = 0.009). 
LSD post hoc analysis revealed a significant overall between group 
difference between WT mice and Tg + Normosol (P = 0.007), 
and Tg + MSC (P = 0.002). LSD post hoc analysis also revealed 
an overall between group trend between Tg + Normosol and tg + 
BDNF hMSC (P = 0.169). Post hoc one-way analysis of variance 
(ANOVA) was used to analyze differences between groups at vari-
ous time points. Significant differences were observed between: 
WT and Tg + Normosol at baseline at weeks 2, 3, 5, 6, and 7; WT 
and Tg + MSC BDNF MOI 10 at baseline, and at week 3; WT and 
Tg + MSC at baseline at weeks 1, 2, 3, 5, and 6; Tg + Normosol 
and Tg + MSC BDNF MOI 10 on weeks 2 and 7; between Tg + 
MSC and Tg + MSC BDNF MOI 10 on weeks 2 and 5. This is a sig-
nificant key behavioral improvement between the YAC128 MSC/
BDNF-treated group and the YAC128 sham treatment control. 
These data demonstrate a significant behavioral amelioration in 
HD mice receiving MSC/BDNF (Figure 5). With distance trav-
eled not significantly different across treatment groups, the signif-
icant increase in time in center for transgenic mouse treated with 
MSC/BDNF indicates a decrease in anxiety rather than purely an 
increase in locomotor activity.
MSC/BDNF efﬁcacy: striatal volume
Following behavioral testing, mice from each of these groups were 
euthanized and their brains were sectioned and stained to assay 
striatal volume using an imaging modality. Striatal atrophy was 
measured by comparison to the age-matched wild type control 
mice, which were assigned the baseline of striatal atrophy of zero. 
Transplantation of MSC alone or MSC/BDNF significantly atten-
uated striatal atrophy (Figure 6). The nonmodified MSCs had an 
effect in reducing the striatal atrophy, to a lesser extent than MSC/
BDNF. One-way ANOVA revealed no overall between-group 
Figure 5 Open-ﬁeld analysis to measure anxiety. (a,b) Each animal 
was placed into an open arena once a week and monitored for 10 min-
utes. All data was collected using Fusion system software. Total distance 
traveled is a measure of spontaneous exploration and is an indicator 
motor ability. The time in the center zone of the box was measured to 
test anxiety. * = Signiﬁcant to WT; # = Signiﬁcant to Tg + Normosol; † = 
Signiﬁcant to Tg + MSC; n = 16–17/group.
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Figure 6 Striatal atrophy. Following completion of behavioral analysis 
in the YAC128 efﬁcacy study, animals were euthanized and formalin per-
fused. Brains were cryosectioned at 30 μm and labeled with cytochrome 
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striatal volume was calculated using the Cavalieri principle for volume 
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differences (F(3,59) = 1.631, P = 0.193). However, LSD post hoc 
analysis revealed a significant difference between WT and tg + 
Normosol (P = 0.038), but no such significant difference was 
observed between WT and tg + WT hMSC (P = 0.129) or WT 
and tg + BDNF hMSC (P = 0.252), suggesting that these cells have 
an intermediate effect following transplantation. A significant 
decrease in striatal volume was observed between vehicle treated 
HD mice and wild-type mice (11.2% striatal atrophy). This sig-
nificant decrease in volume was not observed in the HD mice that 
received MSC/BDNF, which displayed only 6.03% striatal atrophy. 
Mice that received unmodified MSC displayed 8.47% striatal atro-
phy. Thus, administration of MSC/BDNF resulted in an interme-
diate effect, suggesting reduced striatal atrophy.
MSC/BDNF efﬁcacy: neurogenesis
To elucidate a potential underlying mechanism of these therapeu-
tically beneficial effects, we investigated whether neurogenesis may 
be increased with MSC/BDNF treatment in the R6/2 HD model. 
Neurogenesis assays were performed in the R6/2 mouse model of 
HD due to their early disease progression and very rapid decline, 
which more closely recapitulates the rapid progression of juvenile 
HD (JHD), than adult HD. The R6/2 strain only lives for 13–17 
weeks in our colony, making repeated measures after immune sup-
pression and surgery difficult. However, they are a useful strain for 
measuring the effects of MSC/BDNF and other agents on neuro-
genesis, and for examining agents that might extend lifespan.
All R6/2 mice in the study were immune suppressed using 
FK506/Rapamycin delivered by an Alzet osmotic pump. Mice 
were intrastriatally injected with vehicle, MSC or MSC/BDNF 
at 7 weeks of age, and euthanized at 10 weeks of age to evaluate 
neurogenesis. An increase in expression of an immature neuronal 
marker, doublecortin, was observed in the subventricular zone of 
the mice receiving MSC or MSC/BDNF treatment as compared 
to vehicle-treated controls (Figure 7). One-way ANOVA revealed 
an overall between-group differences (F(3,26) = 5.196, P = 0.007). 
LSD post hoc analysis revealed a significant difference between 
WT and Tg + MSC BDNF MOI 10 (P = 0.032), WT and Tg + 
MSC (P = 0.002), and Tg + MSC to Tg + Normosol (P = 0.009). 
A trend was observed between Tg + MSC BDNF MOI 10 and Tg 
+ Normosol (P = 0.121). Taken together, this data suggests that 
transplantation of MSC with and without BDNF significantly 
increases neurogenesis activity in the subventricular zone. These 
data demonstrate that transplantation of MSC and MSC/BDNF 
leads to an increase in endogenous neurogenesis, which could 
potentially slow the progression of the disease.
MSC/BDNF efﬁcacy: lifespan
Improved survival in R6/2 mice is a widely accepted and validated 
endpoint in this HD model. The expected lifespan, as analyzed 
with Kaplan-Meier, revealed that a 9.44% increase was observed 
in R6/2 that received WT MSC, a 7.23% increase was observed in 
R6/2 that received MSC BDNF MOI 10, and a 14.96% increase was 
observed in R6/2 that received MSC BDNF MOI 20 (Figure 8) as 
compared to Normosol-treated R6/2. These data demonstrate that 
MSC/BDNF treatment is neuroprotective and extends the lifespan 
of the R6/2 model of HD.
DISCUSSION
The current studies were performed to validate efficacy for a com-
bined cell and gene therapy product designed to treat HD using 
adult human MSCs to deliver the neurotrophic factor, BDNF. 
Studies have shown BDNF to be an important factor in both neu-
ronal survival and neurogenesis, making it a prime therapeutic 
target for neurodegenerative disorders.27 The MSC/BDNF devel-
opment candidate combines the demonstrable beneficial effects of 
MSC administration to the striata with the benefits of BDNF sup-
plementation. Unlike BDNF delivery via viral vectors or recom-
binant protein administration into the brain, MSCs migrate into 
the areas of damage and independently have numerous beneficial 
tissue healing effects (reviewed in ref. 42).
BDNF expression is diminished in both human HD post-
mortem brain as well as in HD transgenic mouse brain. In rodent 
Figure 7 Neurogenesis. Three weeks following transplantation of MSC, MSC/BDNF MOI 10, or vehicle control (Normosol-R), the 10-week-old 
R6/2 mice were euthanized and formalin perfused. Brains were cryosectioned at 30 μm and labeled using doublecortin and AlexaFluor488. The 
 subventricluar zone was imaged using a Zeiss Axioskop 2 microscope (10× objective) and average ﬂuorescent intensity was calculated using ImageJ. 
* = Signiﬁcant to WT, # = Signiﬁcant to R6/2 + Normosol. n = 6–7/group.
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models of HD, exogenous delivery of BDNF has been shown by 
several groups to ameliorate symptoms, attenuate the neurode-
generative process, and to extend survival.5,9–35
MSCs have been shown to promote endogenous neuro-
nal growth, decrease apoptosis and regulate inflammation via 
the secretion of a robust profile of trophic factors. MSCs have 
been shown to modify the microenvironment of damaged tis-
sue through enhanced neural regeneration and protection.67,68 
Published, peer reviewed proof of concept studies from mul-
tiple laboratories have demonstrated efficacy for MSC, BDNF, 
or murine MSC/BDNF cells in HD mouse models (Reviewed by 
Fink et al.37).
Dey et al.27 demonstrated improvements in the behavioral 
phenotype and reduction in striatal degeneration in HD mouse 
models after intrastriatal administration of murine MSC/BDNF. 
MSCs do not permanently engraft in host tissues and generally 
only persist for several months. However, studies have shown that 
the duration of the MSC-based BDNF production should be suf-
ficient to yield beneficial therapeutic effects in HD brains, since 
the neurorestorative effects of BDNF should outlast the survival of 
MSCs.18,20,27,54–60 This is supported by animal data18,20,27,54–60 and val-
idated in the present preclinical study using human cells (MSC/
BDNF).
The current preclinical studies tested whether human MSC/
BDNF cells have the same therapeutic effect as seen in the previ-
ous murine studies, and were performed in two different murine 
models of HD: YAC128 and R6/2. The models for each primary 
efficacy studies were chosen due to their unique features and 
disease-progression as it relates to Huntington’s disease. While 
there is no perfect animal model for HD, or any neurodegenera-
tive disease, the YAC128 and R6/2 capture key phenotypes of the 
disease. The YAC128 mouse model contains the full human hun-
tingtin gene and presents a subtle disease progression resulting 
in transient behavioral deficits and a slow, progressive cell loss in 
the striatum. The R6/2 model contains only the toxic fragment 
of exon 1 and displays shortened survival. The R6/2 model does 
not display robust neuronal loss as it is likely that the lifespan of 
these mice is too truncated for the neuronal dysfunction to result 
in a quantifiable and significant loss of cells or measurable striatal 
atrophy. We designed our test parameters for both the strengths 
and limitations of both models. For example, it would not be 
experimentally sound to study survival in the YAC128 as they do 
not exhibit a shorter lifespan than their wild-type littermates or to 
study the ability of the MSC to prevent neuronal loss in the R6/2 
as there is no robust cell loss in the striatum. Therefore we tested 
neurogenesis and lifespan in the R6/2 model and behavior and 
striatal atrophy in the YAC128 model.
Mice were immune suppressed to allow for the extended reten-
tion of the human MSC/BDNF cells (Figure 4). Sham-treated and 
cell-treated mice were all immune suppressed and randomized 
between groups prior to each experiment, which were all con-
ducted in a double-blinded manner. Importantly, in contrast to 
the Normosol-treated mice, the YAC128 mice treated with MSC/
BDNF did NOT have significant levels of striatal atrophy, in com-
parison to wild-type mice. MSC without the additional BDNF 
expression had an intermediate effect. These data are important 
because an attenuation of striatal atrophy is the most important 
and definitive efficacy endpoint to be obtained in a planned future 
human clinical trial of MSC/BDNF.
Anxiety is a hallmark of clinical Huntington’s disease and has 
been extensively characterized using the open field in transgenic 
mice and toxic lesion models of Huntington’s disease. Multiple HD 
transgenic mouse models reveal impairments in behavior in open 
field testing.18,69–74 In murine models, anxious mice spend less time 
in the center quadrant of an open field as anxiety increases.18,69–74 
In the current studies, there were no overall motor deficits 
since total distance was equivalent between groups (Figure 5a). 
However, sham-treated HD mice spent much less time in the cen-
ter quadrant of the open field as compared to wild-type controls, 
indicating the HD mice were displaying higher levels of anxiety, as 
expected. This display of anxiety was significantly reduced in HD 
mice that were treated with MSC/BDNF (Figure 5b).
In the current studies, a significant increase in neurogene-
sis-like activity was observed in the subventricular zone in mice 
receiving transplantations of MSC/BDNF. MSC/BDNF treatment 
also resulted in a trend toward an increased lifespan of the R6/2 
mice. These data suggest that MSC/BDNF could work through 
mechanisms of stimulating endogenous neurogenesis. Increasing 
Figure 8 Implantation of MSC/BDNF increased the lifespan of R6/2 mice. Kaplan-Meier analysis: 10% increase for WT MSC, 7.7% increase for 
MSC/BDNF MOI 10, 15.5% increase for MSC/BDNF MOI 20. n = 7–9 mice per group.
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neurogenesis and striatal neuron survival is a key endpoint of a 
planned future clinical trial involving MSC/BDNF. Benraiss et al 
used adeno-associated virus (AAV) vectors to express BDNF in 
striatal neurons and demonstrated that AAV delivery of BDNF-
induced neurogenesis and promoted a longer lifespan in a murine 
model of HD.20 The observed benefit in their studies was potenti-
ated by coexpression of noggin, which is a factor secreted by mes-
enchymal stem/stromal cells (MSCs).38–41
In the current studies conducted for efficacy, there was no 
evidence of weight loss or increased seizures, due to the product, 
no brain abnormalities observed, and no evidence of inflamma-
tion or tumor formation. No migration into spinal cord has ever 
been seen via luciferase. Extensive rule-out tumorigenicity studies 
were performed and the product is safe by these measures. No 
abnormal growth was ever found in the brain or other tissues of 
any mouse tested. Unbiased stereology showed no abnormalities, 
when comparing sham-injected and vehicle-injected brains. Based 
on the efficacy and preliminary safety data reported here, we will 
be performing the definitive assessments required to potentially 
gain FDA approval for the use of human MSC/BDNF cells in a 
proposed future clinical trial for HD.
Numerous clinical trials have demonstrated the biosafety of 
systemic infusion of allogeneic MSCs into patients with various 
diseases without tissue matching, as MSCs are considered relatively 
immune privileged (reviewed in refs. 45,75–77). MSCs have been intra-
cranially and intrathecally injected in previous phase 1-2 clinical 
trials for diseases other than HD, without adverse events.50,53,78–82
Additional studies of MSC injection or implantation into the 
CNS are ongoing or recently completed. Celgene Corporation 
is approved for a multi-center phase 2 clinical trial to use pla-
centa-derived MSC for treating stroke, delivered into the brain 
(clinicaltrials.gov ID# NCT01310114). Placebo controlled tri-
als for MSC injection into the CNS for TBI and stroke, as well 
as spinal cord injury and neurodegenerative disorders are cur-
rently ongoing (clinicaltrials.gov).83 Athersys recently concluded 
patient enrollment of a phase 2a clinical study for ischemic stroke 
patients treated with an MSC-like stem cell therapy referred to 
as MultiStem. The company Brain-Storm Cell Therapeutics Inc. 
reported in early 2015 that it treated the first patients with amy-
otrophic lateral sclerosis with a genetically modified bone mar-
row-derived stem cell (NurOwn). No stem cell-related serious 
adverse events have occurred in any of these studies which pro-
vide extensive safety and provisional efficacy data for nonmatched 
allogeneic bone marrow-derived MSC administration to patients 
through FDA-approved clinical trials.
SanBio conducted a phase 1/2 gene-modified MSC clinical 
trial with administration into the brain to treat stroke (clinical-
trials.gov ID# NCT01287936). This clinical trial uses “next gen-
eration” gene modified cells and thus shares similarities with the 
proposed trial design for our MSC/BDNF product. Our proposed 
future clinical trial (HD-CELL) is designed to demonstrate the 
safety of intrastriatal implantation of gene-modified MSCs to 
treat HD and targets patient accrual from the ongoing observa-
tional study (PRE-CELL) at the University of California Davis 
(ClinicalTrials.gov study identifier NCT01937923).
Monitoring of the safety aspects of MSCs has been rigor-
ously performed throughout these trials and no infusion or 
implantation-related adverse events have been reported, demon-
strating the potential safety of MSC infusion into the brain when 
performed carefully and according to specific clinical regimens, 
including appropriate manufacturing processes (reviewed in 
Sharma et al. 84).
The planned surgical techniques are based on years of pre-
vious fetal striatal implantation techniques and protocols well 
described by Dr. Bachoud-Levi’s group in France85–89 and Rosser 
and Dunnet’s group in the United Kingdom.90–93 The preclinical 
animal model efficacy data presented here, when coupled with 
in vivo biosafety data, supports proceeding down the FDA clini-
cal trial pipeline. Given the strong safety record of MSCs in the 
clinic, our current preclinical efficacy data and the lack of effec-
tive available treatments for HD patients, we propose MSC/BDNF 
treatment has a favorable benefit-to-risk ratio and warrants clini-
cal investigation.
Our stem cell-based delivery system for BDNF sets the prec-
edent for cell-based therapy in the brain and could potentially be 
modified for neurodegenerative disorders such as Alzheimer’s 
disease, Juvenile HD, ALS, spinocerebellar ataxia (SCA), and 
some forms of Parkinson’s disease. Furthermore, this therapeutic 
platform provides a delivery vehicle for planned future corrective 
gene editing studies.
MATERIALS AND METHODS
MSC isolation and culture. Whole bone marrow was purchased com-
mercially (All Cells, Emeryville CA). To isolate human MSCs, whole 
bone marrow was plated in MSC media composed of Dulbecco’s modi-
fied Eagle medium—high glucose (DMEM HG), supplemented with 10% 
premium select fetal bovine serum (Atlanta Biologicals, Flowery Branch, 
GA), which was lot selected to achieve maximum growth, with additives 
of 1% Penicillin-streptomycin (HyClone, Marlborough, MA) and 1% 
L-Glutamine (HyClone). After 24 hours, nonadherent cells were discarded 
and adherent cells were washed twice with phosphate-buffered saline 
(PBS), then incubated in fresh MSC media. Cells were grown at 37 °C in 
20% O2, 5% CO2. When MSC reached 70–80% confluence, cultures were 
lifted by 7 minutes of trypsinization at a concentration of 0.05% (HyClone)
and reseeded at 1,000 cells/cm2 for further subculture. Media was changed 
every third day.
Lentiviral production
Construction of the pCCLc-MNDU3-BDNF-WPRE vector. A cPPT frag-
ment was cloned into the Cla-1 site downstream of the Rev-responsive 
 element (RRE). pCCLc-X was cut with EcoRV, and the MNDU3 promoter, 
a modified MLV long terminal repeat promoter (that was a kind gift from 
Dr. Donald Kohn) cut Cla-1/Xho-1 and blunted, was cloned into this site. 
WPRE was cut with Cla-1, blunted, and cloned into the blunted Nhe-1 site 
upstream of the 3’LTR. The BDNF gene was generated via PCR of cDNA 
generated from RNA isolated from human bone marrow MSCs using 
the following primers: Forward 5′-ATG ACC ATC CTT TTC CTT ACT 
A-3′. Reverse: 5′-CTA TCT TCC CCT TTT AAT GGT C-3′. The BDNF 
was then cloned into pCR2.1 TOPO, then excised with EcoRI and cloned 
into the EcoRI site downstream of the MNDU3 promoter in the pCCLc-
MNDU3-X-WPRE vector.
Construction of pCCLc-MNDU3-Luc-PGK-EGFP-WPRE. A blunted 
Cla-1 WPRE was cloned into the Sma-1 site of pCCLc-MNDU3-LUC-
PGK-EGFP (gift from Dr. Donald Kohn).
Packaging. Lenti-X 293 cells (Clonetech, Mountain View, CA) were 
transfected with 25 μg pCCLc-MNDU3-Luc-PGK-EGFP-WPRE or 
pCCLc-MNDU3-BDNF-WPRE, 25 μg 8.9 packaging plasmid, and 5 μg 
VSVG envelope plasmid using Trans-It 293 Transfection Reagent (Mirus, 
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Madison, WI) in DMEM HG (HyClone). The following day, media was 
changed to Ultraculture Serum Free Media (Lonza, Walkersville, MD). The 
virus was harvested 52 hours later using Centricon Plus-70 PL-100 Filter 
Device (Millipore, Billerica, MA). The final product was filtered using 
0.45-μm Costar Spin-X Centrifuge Filter Tubes (Millipore), aliquoted, 
and stored at −80 °C. Vector titer was quantified using the ABM Lentiviral 
qPCR Titer Kit and Evagreen Mastermix-R (abm, Richmond, BC, Canada). 
Replication Competency Testing was performed using the ZeptoMetrix 
HIV-1 p24 Antigen ELISA 2.0 Kit (ZeptoMetrix, Buffalo, NY).
Transduction. MSCs were plated at a density of 5,000 cells/cm2. The 
following day, the titered lentivirus was added to the culture medium at 
the indicated MOI in the presence of 10 mg/ml protamine sulfate (MP 
Biomedical, Santa Ana, CA). After 24 hours, cells were either trypsin-
ized and cryopreserved or the medium was replaced to allow for further 
culture. Transduction efficiency was determined by flow cytometry for 
vectors containing fluorescent markers on an FC500 (Beckman Coulter, 
Indianapolis, IN).
BDNF detection. Transduced cells were thawed into six-well plates (1 × 105/
well), incubated in 20% O2 for 24 hours and in 1% O2 for an additional 48 
hours. MSC media was changed to serum-free media after 24 hours in 1% 
O2 and collected for ELISA after an additional 24 hours. BDNF levels were 
determined by ELISA (Human BDNF Quantikine ELISA, R&D Systems, 
Minneapolis, MN) immediately after media collection.
Vector copy number. Human MSCs were transduced with pCCLc-
MNDU3-BDNF-WPRE at the indicated MOI, cryopreserved, thawed, 
and expanded for 3 days. DNA was isolated (Wizard Genomic DNA 
Purification Kit, Promega) and used for qPCR analysis. Primers/probes 
were designed based on published sequences and are as follows: GAPDH- 
5′-ACA GTC AGC CGC ATC TTC-3′ and 5′-CTC CGA CCT TCA CCT 
TCC-3′, WPRE—5′-TTA CGC TAT GTG GAT ACG CTG-3′, 5′-TCA 
TAA AGA GAC AGC AAC CAG G-3′ and 5′ /56-FAM/ AGG AGA AAA 
TGA AAG CCA TAC GGG AAG C /36-TAMSp/ 3′. Quantitative PCR 
was performed using SYBR Green PCR Master Mix (Life Technologies, 
Waltham, MA), TaqMan Universal PCR Master Mix, no AmpErase UNG 
(Life Technologies), and the indicated primers/probes under the following 
reaction conditions on an ABI 7300: Stage 1—50 °C for 2 minutes, Stage 
2—95 °C for 10 minutes, Stage 3—40 cycles of 95 °C for 15 seconds and 60 
°C for 1 minute, Stage 4 (dissociation)—95 °C for 15 seconds, 60 °C for 1 
minute, 95 °C for 15 seconds, and 60 °C for 15 seconds. Quantification was 
based on standard curves of plasmid DNA. Vector copy number/cell was 
determined as WPRE/2GAPDH.
Stability of vectors in transduced cells. To determine whether there 
were any deletions or rearrangements in vector-transduced cells, 
genomic PCR was performed. Total genomic DNA was extracted 
from nontransduced, and BDNF vector-transduced MSC using 
the Quick gDNA MiniPrep kit (Zymo Research, Irvine, CA). PCR 
was performed using high-fidelity Taq (Affymetrix, Santa Clara, 
CA). Primers corresponding to the specific vector transgenes were 
used: ψ (forward) 5′-ACCTGAAAGCGAAAGGGAAAC-3′, U5-3′  
(reverse) 5′-CTGCTAGAGATTTTCCACACTGAC-3′, MNDU3 (forward) 
5′-CGCCCT CAGCAGTTTCTAG-3′, MNDU3 (reverse) 5′-CTATCT 
ATGGCTCGTACTCTATA-3′, BDNF (forward) 5′-CCATAAGGACGC 
GGACTTGTA-3′, and BDNF (reverse) 5′-GAGGAGGCTCCAAAGG 
CACTT-3′. PCR products were analyzed and visualized on an agarose gel.
MSC lineage differentiation. MSCs were differentiated into an osteo-
genic lineage by plating at approximately 10,000 cells/cm2 and culturing 
for 16 days in DMEM HG containing 10% fetal bovine serum (FBS), 1× 
L-glutamine, 0.2 mmol/l ascorbic acid, 0.1 μmol/l dexamethasone, and 
10 mmol/l β-glycerophosphate with medium changes every 2 days. For 
adipogenic differentiation, MSC were plated at approximately 10,000 
cells/cm2 and cultured for 16 days in DMEM HG containing 10% FBS, 1× 
L-glutamine, 0.5 mmol/l isobutylmethyxanthine, 50 μmol/l indomethacin, 
and 0.5 μmol/l dexamethosone with medium changes every 2 days (Ogawa 
et al.94). Plates were washed with PBS (+Calcium/+Magnesium), fixed in 
formalin for 5 minutes, washed, then stained with Alizarin Red S Indicator 
(RICCA, Arlington, TX) or Oil red O Solution (Electron Microscopy 
Sciences, Hatfield, PA) for 5 minutes. Plates were then washed for image 
analysis using a 10× objective on a Nikon Eclipse microscope.
Cell proliferation. MSCs were plated at approximately 1,000 cells/cm2 
in 24-well plates and cultured as described. After 1, 3, 5, 7, and 9 days 
in culture, plates were analyzed using CellTiter96 Non-radioactive Cell 
Proliferation Assay (Promega, Madison, WI), following the manufacturer’s 
protocol. MTT dye solution was added directly to culture medium. The 
plate was returned to the incubator for 2 hours before halting the reaction 
with stop solution. Samples were stored at 4 °C until completion of the 
time course, at which time the plates were returned to 37 °C for 2 hours 
until the dye crystals had fully dissolved. Then, 100 μl from each well was 
loaded into a 96-well plate, which was analyzed for absorbance at 570 nm 
with a reference at 650 nm on a microplate spectrometer (Emax, Molecular 
Devices, Sunnyvale, CA). The number of cells was calculated from a stan-
dard curve generated from known numbers of cells treated identically to 
the above using a linear regression.
In vivo imaging study. Whole bone marrow was purchased commer-
cially (Lonza, Walkersville, MD) and MSCs were isolated, transduced, 
and expanded as described.95 Immune-competent FVB/NJ (Friend Virus 
B NIH Jackson) mice and immune-deficient NSG (NOD SCID γ-/-) mice 
bred in-house were used for this study at 4 months of age. Human MSCs 
were transduced by a lentiviral vector carrying the luciferase gene (pCCLc-
MNDU3-Luc-PGK-EGFP-WPRE), which allows cells to be visualized in 
the brains of living mice over time (MSC-Luc). FVB/NJ animals (3M/2F) 
were assigned to the following groups: noninjected (imaging control), 
MSC-Luc or MSC-Luc + Immune suppression (FK506/Rapamycin deliv-
ered by Alzet osmotic pump as described below). Additionally, immune-
deficient NSG mice (3M/2F) were injected with MSC-Luc as positive 
controls. Unilateral striatal implantation of passage 5 MSCs was performed 
as described above (2.5 × 105 cells in the left hemisphere).
Bioluminescence was detected in anesthetized animals via IVIS 
Spectrum (Perkin Elmer, Waltham, MA) (Perkin Elmer) 15 minutes 
postintraperitoneal luciferin injection (3 mg/mouse, XenoLight 
D-Luciferin K+ Salt, Perkin Elmer). Mice were imaged on post-op days 
2, 4, 7, 9, 11, 14, and then weekly for 5 weeks. Animals used in this study 
were housed under normal 12-hour light/12-hour dark cycle conditions. 
All procedures were reviewed and approved by the UC Davis Institutional 
Animal Care and Use Committee (IACUC).
Animals. YAC128: YAC128 mice (Jackson Labs stock #004938, Bar Harbor, 
ME) were immune suppressed by receiving FK506 and Rapamycin (1 
μg/g/day each) by Alzet osmotic pumps (Model 1004, Alzet Osmotic 
Pumps, Cupertino, CA) implanted subcutaneously four days prior to 
cell implantation. Pumps were preloaded with FK506/Rapa diluted in 
50%DMSO/50%PEG and incubated in Normosol-R @ 37 °C × 48 hours 
prior to implantation. FK506 (Tacrolimus) and Rapamycin (Sirolimus) 
were purchased from InVivoGen, San Diego, CA. Mice were implanted 
bilaterally into the striata with vehicle, MSC or MSC/BDNF MOI 10 at 8 ½ 
months of age. Mice received 5 × 105 cells (passage 6) per hemisphere in 5 
μl vehicle. Behavioral data was collected weekly following cell implantation 
until 10 months of age (initial behavioral training and testing began at 4 ½ 
months). At 10 months of age, animals were euthanized and brains were 
collected for histological analysis. This study was run in two cohorts and 
data was combined for statistical analysis.
R6/2: R6/2 120CAG (Jackson Labs stock #006494) mice were immune 
suppressed using FK506/Rapamycin delivered by an Alzet osmotic pump 
as described above. Mice were bilaterally implanted into the striata with 
vehicle, MSC, MSC/BDNF MOI 10 or MSC/BDNF MOI 20 at 7 weeks 
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of age. Mice received 5 × 105 cells (passage 6) per hemisphere in 5 μl 
vehicle. Behavioral testing began at 6 weeks of age and continued weekly 
following cell implantation. Mice were sacrificed 3 weeks following cell 
implantation in order to process the brains for histology. An additional 
cohort of nonimmune-suppressed animals was used to collect survival 
data following the UC Davis IACUC guidelines on humane endpoints.
All mice were individually housed on a reverse light cycle with food 
and water ad libitum for the duration of the study. All procedures were 
reviewed and approved by the UC Davis IACUC.
Surgical procedures and monitoring. All surgical procedures were con-
ducted in compliance with the UC Davis IACUC policy on rodent survival 
surgery.
Alzet pump implantation. Prior to surgery, hair was removed using 
a depilatory. Animals were anesthetized using isoflurane (2–3% in oxy-
gen). Skin was cleaned with betadine and wiped clean with an alcohol pad. 
Alzet pumps (Model 1004, Alzet Osmotic Pumps, Cupertino, CA) were 
implanted subcutaneously through a small incision between the scapulae 
with the flow moderator portion of the pump pointing away from the inci-
sion. The skin incision was then closed with 6-0 silk suture.
Cell preparation. Prior to surgery, cells were thawed and incubated 
at 37 °C in 20% O2, 5% CO2 for 24 hours. Subsequently, the media was 
changed and cells were further incubated at 37°C in 1% O2, 5% CO2 for 
an additional 48 hours prior to implantation as previously described.96,97
Cell implantation. Prior to surgery, hair was removed from the head 
using Nair. Animals were anesthetized using isoflurane (2–3% in oxygen) 
and placed into a stereotaxic frame. Skin was then cleaned with betadine 
and wiped clean with an alcohol pad. A small incision was made in the 
scalp to allow visualization of the skull. A small (1 mm) burr hole was made 
in the skull at 0.5 mm AP and ±2.0 mm ML relative to bregma. Cells were 
injected into the striatum at a depth of 2.5 mm using a Hamilton syringe at 
a rate of 0.5 μl/minute in a total volume of 5 μl. After waiting an additional 
5 minutes after injection, the syringe was slowly removed, the burr holes 
were filled with bone wax and the incision sutured with 6-0 silk suture.
Pain management. Carprofen (5 mg/kg) was administered by subcu-
taneous injection at the time of surgery and again the following day. All 
postoperative animals were observed daily for 7 days in order to monitor 
recovery and incision healing.
Open ﬁeld. Each animal was placed into the center of an open arena 
once a week and monitored for 10 minutes. All data was collected using 
Fusion system software. Technicians performing the assays were blinded 
to implantation group in all studies.
Histology. Following completion of behavioral analysis, animals were sac-
rificed and transcardially perfused with saline solution followed by forma-
lin (PROTOCOL, Kalamazoo, MI). Brains were harvested, weighed, fixed 
in formalin at room temperature for 24 hours, transferred to a 30% sucrose 
solution at 4 °C for 24–48 hours then cryopreserved by submersion in dry 
ice cooled isopropyl alcohol for 5 minutes. Brains were then wrapped in 
foil and stored at −80 °C. Brains were prewarmed to −20 °C and cryosec-
tioned at 30 μm.
For analysis of endogenous neurogenesis occurring in the 
subventricular zone in response to the MSC transplantation, the tissue 
was labeled with anti-Doublecortin (rabbit Doublecortin; 1/500, Abcam 
18723, Cambridge, MA), a label of immature neurons. The tissue was 
incubated in blocking solution for 45 minutes at room temperature 
(blocking solution: 2% normal goat serum, 1% bovine serum albumin, 
0.1% Triton-X, 0.05% Tween-20 in 0.01M PBS). The tissue was then 
transferred to a well containing the primary antibody and stored at 
4  °C overnight with gentle agitation. The following day, the tissue was 
rinsed three times in PBS and transferred to a well containing anti-rabbit 
AlexaFluor488 (1/300; Invitrogen, Grand Island, NY) for 1 hour at room 
temperature and given gentle agitation. The tissue was then rinsed three 
times in PBS and coverslipped using Fluoromount (Sigma, St. Louis, MO).
Cytochrome oxidase histology was used to delineate structures in the 
brain and was used for volumetric analysis. The tissue was submersed in a 
solution of 800 mg sucrose, 4 mg of cytochrome C (Calbiochem, Billerica, 
MA), and 1 mg of 3,3′-Diaminobenzidine tetrahydrochloride (Sigma) 
dissolved in 20 ml of PBS for 4 hours at room temperature with gentle 
agitation. The tissue was then transferred to deionized H2O, mounted 
onto positively charged glass slides, and coverslipped using Permount 
(Fisher, Waltham, MA).
Image acquisition and analysis. Images of the fluorescent labels were cap-
tured using a Zeiss Axiskop 2 plus fluorescent microscope at 10× magni-
fication. Cytochrome oxidase-labeled tissue was imaged using a Keyence 
BZ-9000 at 4× and then images were stitched together using Keyence 
viewer software. Images were captured from nine levels, centered at the 
transplant site with additional sections anterior and posterior to the trans-
plant site, approximately 180 μm apart.
All images were analyzed using ImageJ (NIH, Bethesda, MD). Average 
intensity of doublecortin was measured in the subventricular zone of each 
group. Striatal volume was calculated using Cavalieri’s volume estimation.
Statistics. All statistical analyses were performed using SPSS v22 with an 
α-level equal to 0.05. All behavioral data was analyzed using a repeated 
measures ANOVA to measure changes between genotypes and treatments 
across weeks. Histological data was analyzed using a one-way ANOVA. 
When appropriate, a LSD post hoc was performed. Survival was analyzed 
using Kaplan-Meier analysis.
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